Exploring cannabinoid receptor CB1 autophagy and the obesity phenotype of p62-deficient mice.
| Journal | Biochemistry and biophysics reports |
| Study Type | Clinical Study |
| Population | Human participants |
This preclinical study elucidates how CB1 receptors are regulated through autophagy pathways and provides mechanistic insights into metabolic dysfunction. Understanding CB1 receptor turnover may inform therapeutic strategies for obesity and metabolic disorders where the endocannabinoid system plays a central role.
This laboratory study used mouse models to investigate the relationship between autophagy receptor p62, CB1 receptor degradation, and metabolic phenotypes. Researchers found that CB1 receptors undergo autophagy-dependent degradation in neurons, and that p62-deficient mice develop late-onset obesity with elevated hypothalamic endocannabinoid levels but without increased food intake. The study suggests CB1 receptor signaling changes may contribute to metabolic dysfunction through altered energy expenditure rather than appetite regulation.
“This adds important mechanistic detail to our understanding of endocannabinoid system regulation, though it’s purely preclinical work. The finding that obesity can occur without hyperphagia in this model reinforces that metabolic effects of cannabinoids extend well beyond appetite stimulation.”
💬 Join the Conversation
Want to apply this research to your care?
CED Clinic translates emerging research into individualized clinical care. Dr. Caplan has treated 30,000+ patients.
Book a consultation →Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
- FAQ
- How does autophagy affect CB1 receptor function in the brain?
- Can defects in autophagy proteins like p62 contribute to obesity development?
- Does p62 deficiency directly affect CB1 receptor levels in metabolically relevant brain regions?
- What role do endocannabinoids play in obesity associated with autophagy dysfunction?
- Are there clinical implications for targeting CB1 receptors in metabolic disorders involving autophagy?
- Read next
FAQ
How does autophagy affect CB1 receptor function in the brain?
This study demonstrates that CB1 receptors are subject to autophagy-dependent degradation, as blocking autophagy led to substantial CB1 receptor accumulation in neurons. Interestingly, CB1 receptor activation partially reduced this accumulation, suggesting that receptor stimulation influences its own turnover through autophagy pathways.
Can defects in autophagy proteins like p62 contribute to obesity development?
Yes, mice lacking the autophagy receptor p62 developed late-onset obesity without increased food intake, suggesting metabolic dysfunction rather than overeating as the cause. These mice also showed early hypoactivity and elevated levels of the endocannabinoid 2-AG in the hypothalamus, indicating disrupted energy metabolism regulation.
Does p62 deficiency directly affect CB1 receptor levels in metabolically relevant brain regions?
Surprisingly, p62 deficiency did not significantly alter CB1 receptor protein abundance in the brain or hypothalamus despite p62’s role in autophagy. However, the signaling downstream of CB1 receptors (ERK1/2 pathway) was modestly reduced in the hypothalamus, suggesting functional rather than quantitative changes.
What role do endocannabinoids play in obesity associated with autophagy dysfunction?
The study found elevated hypothalamic 2-arachidonoylglycerol (2-AG) levels in p62-deficient obese mice, indicating dysregulated endocannabinoid signaling. This suggests that autophagy dysfunction may contribute to obesity partly through alterations in endocannabinoid system activity, particularly in brain regions controlling metabolism.
Are there clinical implications for targeting CB1 receptors in metabolic disorders involving autophagy?
While this preclinical research shows interesting connections between autophagy, CB1 receptors, and metabolism, the clinical relevance remains in early stages requiring further evidence. The findings suggest that therapies targeting CB1 receptors might need to consider autophagy status, but human studies are needed to validate these mechanistic insights.
![[Low-grade inflammation in musculoskeletal disorders: biological basis and role of PRGF].](https://cedclinic.com/wp-content/uploads/2026/04/tmp98vtqu6o-150x150.jpg "Exploring cannabinoid receptor CB1 autophagy and the obesity phenotype of p62-deficient mice.")